Pictorial Representation of Illness and Self Measure (PRISM)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT01707186
Recruitment Status : Active, not recruiting
First Posted : October 16, 2012
Last Update Posted : October 25, 2017
UCB Pharma
Information provided by (Responsible Party):
University of Oxford

Brief Summary:

PRISM (Pictorial Representation of Illness and Self Measure) has been developed since the mid-1990s; the task was first developed as a simple measure of how a person was coping with his or her experience of illness. This is an international, multicentre study to evaluate the PRISM tool for the assessment of suffering in rheumatoid arthritis at different stages of the illness and the effect of treatment intervention. There are 5 sites: Berlin, Oxford, Limoges, Montreal and Queensland. The study will recruit 200 patients in total.

In addition to the procedures for the patient's routine clinical visit, the patients will be invited to answer a series of questionnaires and donate 20ml blood sample. Patients will be asked to attend 3 times over 24 weeks

Condition or disease
Rheumatoid Arthritis

Study Type : Observational
Actual Enrollment : 220 participants
Observational Model: Cohort
Time Perspective: Prospective
Official Title: Pictorial Representation of Illness and Self Measure
Study Start Date : October 2012
Actual Primary Completion Date : June 30, 2017
Estimated Study Completion Date : June 30, 2018

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Arthritis

Group 1A
Early phase, requiring change in treatment
Group 2
Established phase, stable treatment
Group 2A
Established phase, requiring a change in treatment
Group 1
Early phase, stable treatment

Primary Outcome Measures :
  1. PRISM/PRISM+ [ Time Frame: 30 September 2015 ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Ages Eligible for Study:   18 Years to 90 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population
Patients with rheumatoid arthritis from hospital clinics

Inclusion Criteria:

  • Participant is willing and able to give informed consent for participation in the study.
  • Male or Female, aged 18 years or above.
  • Written confirmed diagnosed of rheumatoid arthritis

Exclusion Criteria:

  • A diagnosis of any of the following:
  • Multiple sclerosis
  • Motor neurone disease
  • Parkinson's disease
  • Alzheimer's disease
  • Depression or anxiety disorders as identified using the Patient depression screening questions from the patient health questionnaire 9 (PHQ9).

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT01707186

United Kingdom
Nuffield Orthopaedic Centre
Oxford, United Kingdom, OX3 7HE
Sponsors and Collaborators
University of Oxford
UCB Pharma
Principal Investigator: Peter Taylor, FRCP, PhD University of Oxford

Responsible Party: University of Oxford Identifier: NCT01707186     History of Changes
Other Study ID Numbers: 2010930
First Posted: October 16, 2012    Key Record Dates
Last Update Posted: October 25, 2017
Last Verified: October 2017

Additional relevant MeSH terms:
Arthritis, Rheumatoid
Joint Diseases
Musculoskeletal Diseases
Rheumatic Diseases
Connective Tissue Diseases
Autoimmune Diseases
Immune System Diseases